Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RISEDRONATE SODIUM

All products: general benefit

Other products in the same Health Canada class (M05B, M05BA) — coverage varies; not interchangeable

  • Alendronate (Fosamax): general benefit, Not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, Not a benefit
  • Etidronate (Didronel): limited Use 236, 237, Not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit
  • Pamidronate (Aredia): not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Teva-Risedronate · DIN 02298392 · 35mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Risedronate · DIN 02298392 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78369 · Verify on the e-Formulary ↗ (DIN 02298392)

Source record
DIN 02298392: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id TEV Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78369
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (10) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: osteoporosis in men, osteoporosis in postmenopausal women
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL ALENDRONATE & CHOLECALCIFEROL · General benefit 1 INDICATIONS FOSAVANCE® (alendronate sodium/cholecalciferol) is indicated for: • The treatment of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph • The treatment of osteoporosis in men. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph RALOXIFENE HCL · Limited Use, codes 373 INDICATIONS AND CLINICAL USE APO-RALOXIFENE (raloxifene hydrochloride) is indicated for the treatment and prevention of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00002184.PDF; date not captured; DIN 02279215; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ACTONEL (risedronate sodium hemi-pentahydrate) is indicated for:  the treatment and prevention of osteoporosis in postmenopausal women1  the treatment of osteoporosis in men, to improve bone mineral density  the treatment and prevention of glucocorticoid-induced osteoporosis in men and women1  Paget's disease of bone1 ACTONEL DR (risedronate sodium hemi-pentahydrate) in indicated for:  The treatment of osteoporosis in postmenopausal women 1Although risedronate tablets 5 mg and 30 mg are available in the marketplace, ACTONEL is no longer marketed in the 5 mg and 30 mg strengths. It may be necessary to use alternate risedronate sodium products to achieve the appropriate dose. Postmenopausal Osteoporosis: In the treatment of osteoporosis in postmenopausal women at risk of fracture, ACTONEL and ACTONEL DR prevent vertebral and nonvertebral osteoporosis-related (fragility) fractures and increase bone mineral density (BMD) at all measured skeletal sites of clinical importance for osteoporotic fractures, including spine, hip, and wrist. Osteoporosis may be confirmed by the presence or history of osteoporotic fra… https://pdf.hres.ca/dpd_pm/00068139.PDF PM date: NOV 3, 2022 Source product: ACTONEL; DIN 02246896; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.